Prosper Animal Health (PAH) is an innovative animal health company headquartered in Doylestown, Pennsylvania. They specialize in creating and commercializing breakthrough vaccines for various livestock and companion animal species. With their internationally patented technology, PAH aims to enhance the effectiveness, diversity, safety, and duration of vaccines.

The management team and scientific advisors at PAH possess extensive global expertise in vaccines, infectious diseases, pharmaceutical drug development, regulatory compliance, and commercialization. Their decades of experience in leading international pharmaceutical companies ensure a high level of professionalism and knowledge. PAH collaborates with key strategic partners in the animal health industry for product development, regulatory compliance, manufacturing, marketing, and distribution.

This ensures that their vaccines meet the highest standards and reach the animals that need them most. One of their transformative technologies is IMT504, a groundbreaking oligodeoxynucleotide (ODN) with remarkable immunostimulatory effects. This technology safely activates important immune cells, leading to robust antibody responses and disease protection.

IMT504 oil-free vaccines are pioneering the future of animal health, providing faster, stronger, and longer-lasting immune responses for healthier and more productive animals. PAH's initial applications of IMT504 include vaccines for salmon aquaculture, poultry (in ovo), dogs, and swine PRRS and FLU. Their commitment to advancing animal health is evident in their dedication to research and development of innovative vaccines.

For more information, visit their website at info@prosperanimalhealth. com